Comparative genomic analyses of pathogenic bacteria and viruses and antimicrobial resistance genes in an urban transportation canal. Jantharadej K, Kongprajug A, Mhuantong W, Limpiyakorn T, Suwannasilp BB, Mongkolsuk S, Sirikanchana K. Sci Total Environ. 2022 Nov 20;848:157652. doi: 10.1016/j.scitotenv.2022.157652. Epub 2022 Jul 26. PMID: 35905960

20 Nov 2022
0
0

Comparative genomic analyses of pathogenic bacteria and viruses and antimicrobial resistance genes in an urban transportation canal.
Jantharadej K, Kongprajug A, Mhuantong W, Limpiyakorn T, Suwannasilp BB, Mongkolsuk S, Sirikanchana K.
Sci Total Environ. 2022 Nov 20;848:157652. doi: 10.1016/j.scitotenv.2022.157652. Epub 2022 Jul 26.
PMID: 35905960

Tags

Share this

Related Posts

The Burkholderia pseudomallei RpoE (AlgU) operon is involved in environmental stress tolerance and biofilm formation. Korbsrisate S, Vanaporn M, Kerdsuk P, Kespichayawattana W, Vattanaviboon P, Kiatpapan P, Lertmemongkolchai G FEMS Microbiol Lett252p243-9(2005 Nov 15)
15 Nov 2005
0

The Burkholderia pseudomallei RpoE (AlgU) operon is involved in environmental stress tolerance and biofilm formation. Korbsrisate S, Vanaporn M, Kerdsuk P, Kespichayawattana W, Vattanaviboon P, Kiatpapan P, Lertmemongkolchai G FEMS Microbiol Lett252p243-9(2005 Nov 15)

The Burkholderia pseudomallei RpoE (AlgU) operon is involved in environmental stress tolerance and biofilm formation. Korbsrisate S, Vanaporn M, Kerdsuk P, Kespichayawattana W, Vattanaviboon P, Kiatpapan P, Lertmemongkolchai G FEMS Microbiol Lett252p243-9(2005 Nov 15)
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More